Zhejiang Medicine Co., Ltd.SSE: 600216

Announcement on "Corporate Value and Return Enhancement" Action Plan

Nov 21, 2024 · Issued by Zhejiang Medicine Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Nov 21, 2024

On 6ix: 6ix.com/news/announcement-on-corporate-value-and-return-enhancement-action-plan-11

Announcement on "Corporate Value and Return Enhancement" Action Plan

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Zhejiang Medicine Co., Ltd. on 6ix

Earlier from Zhejiang Medicine

Indicative Announcement on Changes in Equity Structure of Controlling Shareholder and Actual ControllerOct 30, 2024
Report for Q3 2024Oct 25, 2024
Announcement on Company's Drug Metaraminol Bitartrate Injection Passing Consistency Evaluation of Generic DrugSep 11, 2024
Announcement on Convening the 2024 Semi-Annual Performance BriefingSep 3, 2024
Semi-annual Report in 2024Aug 23, 2024

Later from Zhejiang Medicine

Announcement on Completion of Industrial and Commercial Registration for Changes in Equity Structure of Controlling Shareholder and Change of Actual ControllerDec 23, 2024
Announcement on Expected Increase in Annual Performance for 2024Jan 23, 2025
Announcement on the Subsidiary Zhejiang Novus Pharmaceuticals Co., Ltd. Passing On-site Inspection by FDAFeb 27, 2025
Announcement on Obtaining Drug Registration Certificate for Compound Sodium Acetate Ringer's InjectionFeb 28, 2025
Announcement on the Shareholding Reduction Plan for Shareholders Holding More than 5% of Shares through Call AuctionMar 21, 2025

All Zhejiang Medicine news releases

Follow Zhejiang Medicine into a list and get an email when it puts out news.

Follow Zhejiang Medicine